Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Raltitrexed

X
Drug Profile

Raltitrexed

Alternative Names: D-1694; ICI-D1694; Tomudex; ZD 1694; ZN-D1694

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Institute of Cancer Research
  • Developer AstraZeneca; Centre Georges Francois Leclerc; Hospira; National Cancer Institute (France)
  • Class Antineoplastics; Quinazolines; Small molecules; Thiophenes
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Malignant-mesothelioma

Most Recent Events

  • 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
  • 18 Apr 2018 Centre Georges Francois Leclerc completes a phase II trial in Colorectal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in France (Intra-arterial) (NCT01348412)
  • 21 Jun 2017 Phase-II development for Colorectal cancer in patients with unresectable liver metastases is ongoing in France (Intra-arterial) (NCT01348412)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top